Guggenheim Capital LLC lifted its stake in shares of ResMed Inc. (NYSE:RMD) by 46.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 722,480 shares of the medical equipment provider’s stock after acquiring an additional 229,030 shares during the quarter. Guggenheim Capital LLC owned 0.51% of ResMed worth $61,184,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently bought and sold shares of RMD. Cubist Systematic Strategies LLC purchased a new stake in shares of ResMed during the third quarter worth $113,000. Calton & Associates Inc. acquired a new position in shares of ResMed during the fourth quarter worth $115,000. Conning Inc. acquired a new position in shares of ResMed during the fourth quarter worth $203,000. Commerzbank Aktiengesellschaft FI acquired a new position in shares of ResMed during the fourth quarter worth $206,000. Finally, Dowling & Yahnke LLC acquired a new position in shares of ResMed during the fourth quarter worth $208,000. 62.40% of the stock is currently owned by institutional investors and hedge funds.
In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $84.99, for a total value of $106,237.50. Following the completion of the transaction, the chief financial officer now owns 78,322 shares in the company, valued at $6,656,586.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James Hollingshead sold 600 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total transaction of $50,976.00. Following the completion of the transaction, the insider now owns 62,602 shares of the company’s stock, valued at approximately $5,318,665.92. The disclosure for this sale can be found here. Insiders sold 44,139 shares of company stock valued at $4,398,906 in the last 90 days. 1.77% of the stock is currently owned by insiders.
ResMed Inc. (NYSE RMD) opened at $98.89 on Wednesday. ResMed Inc. has a 12 month low of $67.04 and a 12 month high of $104.78. The stock has a market cap of $14,226.96, a price-to-earnings ratio of 31.70 and a beta of 0.94.
ResMed (NYSE:RMD) last released its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.22. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The company had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. ResMed’s revenue for the quarter was up 13.4% on a year-over-year basis. research analysts forecast that ResMed Inc. will post 3.34 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, February 8th will be paid a $0.35 dividend. The ex-dividend date of this dividend is Wednesday, February 7th. This represents a $1.40 annualized dividend and a yield of 1.42%. ResMed’s dividend payout ratio is presently 70.00%.
TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/03/14/guggenheim-capital-llc-buys-229030-shares-of-resmed-inc-rmd.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.